The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Acupuncture as treatment for hot flushes in patients using anti-oestrogen medication.

EBCC 6 2008

15 - 19 Apr 2008

Published: 4 Dec 2008

Views: 13054

Rating:

Save

Mrs Jill Hervik, Physiotherapist and Acupuncturist, Vestfold Central Hospital, Norway

Mrs Jill Hervik speaks about a study which has has successfully reduced the hot flushes commonly caused by anti-oestrogen medication through acupuncture.

Categories:
Breast

Related Videos

Comment: LUMINA results show that women with low levels of the Ki67 biomarker ca...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

Biomarker guidance allows patients 55 or older with low-grade luminal A-type bre...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A...

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

LUMINA results show that women with low levels of the Ki67 biomarker can avoid o...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

ASCO 2022: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2022: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer wi...

Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San ...

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients ( Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 exp...

Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression ( Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA )

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic b...

Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA )

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast can...

Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA )

More from ecancer